ArticleInternational journal of women's health2025
Effectiveness of Fetal Medicine Foundation's Non-Biochemical Risk Calculation Algorithm in Detection of Common Trisomies Screening at 11-13 weeks of Gestation: 12 Years' Experience in Northern Thailand.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prenatal Screening for Common Aneuploidy in Southeast Asian Countries: A Systematic Review of Challenges and Opportunities.Prenatal diagnosis · 2026Pooled it
- Prenatal Screening for Monosomy X in the First Trimester: A Comparison of a Thai Predictive Model and the Fetal Medicine Foundation Algorithm.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of first-trimester non-biochemical screening using the Fetal Medicine Foundation (FMF) algorithm in predicting fetal common trisomies (trisomy 21, 18, and 13) in clinical practice. Patients and Methods: Between 2011 and 2023, the non-biochemical screening was routinely performed at 11+0-13+6 weeks' gestation in 9591 singleton pregnancies at Maharaj Nakorn Chiang Mai Hospital, Thailand. The individual risks for common fetal trisomies were calculated by combining maternal age, history of common trisomies in a previous pregnancy, nuchal translucency thickness, and fetal heart rate using the official FMF algorithm. Women with risk of ≥1:250 were classified as high risk. The fetal karyotyping results and pregnancy outcomes were reviewed and analyzed. Results: A total of 8491 complete data sets of singleton pregnancies were analyzed. The incidence of common trisomies was 0.5% (46 cases), including 0.3% (28 cases) of trisomy 21, 0.1% (9 cases) of trisomy 18 and 0.1% (9 cases) of trisomy 13. With a cut-off risk of 1:250, FMF algorithm performance for trisomy 21 screening had a sensitivity of 60.7%, specificity of 97.6%, PPV of 7.7%, NPV of 99.9%, and a false positive rate of 2.4%. The performance for detecting all common trisomies demonstrated a sensitivity of 52.2%, specificity of 97.2%, PPV of 9.2%, NPV of 99.7%, and a false positive rate 2.8%. Conclusion: The first trimester non-biochemical FMF algorithm is sufficiently effective in predicting common trisomies, particularly trisomy 21. This simple approach can be easily implemented in clinical practice, including healthcare facilities that lack access to maternal blood testing services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.